RNAZ
Transcode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.60
+1.91%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.59
From 52W high−87.03%
Volume7097.00
Market cap$27.09M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.59
From 52W high
−87.03%
Volume
7097.00
Market cap
$27.09M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
P/E (TTM)
—
RSI (14)
40.9
MomentumView details →
1D Return
+1.91%
YTD Return
−76.43%
SummaryUpdated Jun 1, 2026
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Boston, Massachusetts. The company went public in July 2021 and focuses on developing innovative RNA-based therapeutics and diagnostics specifically targeting metastatic cancer. TransCode operates in the highly specialized field of precision oncology, utilizing advanced RNA interference (RNAi) and gene editing technologies to address one of cancer's most challenging aspects - metastasis, which occurs when cancer cells spread from their original location to other parts of the body.
Similar companies
Latest newsMore news →
TransCode Therapeutics’ board initiated a formal strategic process to evaluate alternatives intended to maximize value, including licensing, development partnerships and other transactions involving the company and its oncology portfolio.7d agoTranscode Therapeutics, Inc. announced that a poster on its TTX-MC138 Phase 1a clinical evaluation was accepted for presentation at the Transcode Therapeutics, Inc. in Madrid on October 23, 2026.16d agoNatera, Inc. and Transcode Therapeutics, Inc. announced a collaboration to support enrollment in TransCode’s Phase 2a trial of TTX-MC138 in patients with colorectal cancer.22d ago